cytokines and chemokines

Improving cancer immunotherapy using G-CSF-blocking antibodies to overcome myeloid cell-mediated immunosuppression

Half of all Canadians will develop cancer and 1 in 4 will die of the disease. Cancer immunotherapy is a promising solution applicable to multiple types of cancer. The immune system plays a critical role in removing tumour cells. However, tumours escape the immune system to continue growing. Immunotherapy can enhance the immune system's ability to fight cancer and, in some cases, achieve long-lasting remission. However, many cancers do not respond to currently available immunotherapies.

Primary Investigator: 
Year: 
2019

Role of TAK1 in resident fibro/adipogenic progenitors. A Key modulator of the inflammatory milieu and a therapeuthic target in chronic diseases

In our aging society, degenerative complications of chronic diseases are on the rise and account for a significant percentage of deaths. Among these, fibrosis is the most common, and yet no therapy capable of mitigating its effects is available. Investigating and understanding the signaling pathways that influence fibrogenic progenitor (FAP) fate will not only elucidate a key component of the regenerative process but may reveal pathways that could be targeted therapeutically to prevent inflammation, fibrosis, and enhance regeneration or maintain muscle homeostasis.

Primary Investigator: 
Award Type: 
Year: 
2019

The role of PCSK9 in clearance of bacterial lipids and the development of anti-PCSK9 treatment for sepsis

Sepsis, which is characterized as an uncontrolled inflammatory response to severe infection, is the leading cause of death in intensive care units. In Canada, sepsis led to a total of 13,500 deaths in 2011, which translates to approximately one in 18 deaths in Canada involving sepsis. Despite this pressing medical need, there are currently no effective treatments for sepsis. 

Primary Investigator: 
Award Type: 
Year: 
2017

IL-37 signaling via SIGIRR: A novel mechanism to suppress intestinal epithelial cell driven inflammation and dysbiosis

Patients with Inflammatory Bowel Disease (IBD) suffer bouts of extreme gut inflammation that disrupt the population of bacteria in their intestines. Consequently, IBD patients often have fewer beneficial bacteria and suffer an overgrowth of potentially dangerous bacteria. In healthy individuals, such responses are typically prevented by SIGIRR, a protein made by the cells that line the gut. 

Primary Investigator: 
Award Type: 
Year: 
2017

Don’t sugar coat it: Cardiac consequences of developing Type 2 diabetes after spinal cord injury

Michael Smith Foundation for Health Research/Rick Hansen Institute (RHI)/International Collaboration on Repair Discoveries (ICORD) Post-Doctoral Fellowship Award

People with spinal cord injury (SCI) are at an increased risk of developing type 2 diabetes. Currently, no studies have investigated type 2 diabetes in people with SCI. We believe it may contribute to the high rate of heart disease among people with SCI.

Primary Investigator: 
Award Type: 
Year: 
2015
Subscribe to RSS - cytokines and chemokines